A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389
COR1389-101
Phase 1 other active
Quick answer
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389 for Obesity / Right heart failure (healthy participants) is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Obesity / Right heart failure (healthy participants)
- Phase
- Phase 1
- Modality
- other
- Status
- active